Elective hysterectomy. Benefits, risks, and costs
other
public-domain-us
⚙
AI-generated summary
by gemini-2.5-flash-lite, 2026-07-15
ⓘ
Elective hysterectomy for benign gynecologic conditions improves life expectancy and quality of life for women ages 30-60 by preventing cancer, but risks include operative mortality and potential life expectancy loss for those with high operative risk or younger women not on estrogen replacement.
Abstract
This study evaluated the effect of hysterectomy or hysterectomy and bilateral salpingo-oophorectomy (hysterectomy and oophorectomy) versus alternative medical management on life expectancy, quality of life, and direct medical costs. Using techniques of decision analysis and available data on sequelae, it was found that gains in life expectancy and quality of life can be expected when women ages 30-60 undergo hysterectomy for benign neoplasm, disorders of menstruation, acquired abnormal anatomy, cervical disease, or endometriosis, owing primarily to prevention of reproductive tract cancers, which outweighs the impact of operative mortality. However, women who have relatively high operative risk or low expected cancer risks, beyond thresholds estimated in sensitivity analyses, suffer losses in life expectancy. Women younger than 35 not treated with replacement estrogens following hysterectomy and oophorectomy can expect net losses in life expectancy with surgical intervention due to increased risks of heart disease and osteoporosis. For women in the reproductive years who wish to preserve their potential to bear children, sterilization may be an unacceptable consequence of elective hysterectomy in the quality of life.
My notes (saved in your browser only)
Condition tags
endometriosis
MeSH descriptors
Hysterectomy
Hysterectomy
Hysterectomy
Hysterectomy
Adult
Age Factors
Castration
Contraception
Contraception
Coronary Disease
Coronary Disease
Coronary Disease
Cost-Benefit Analysis
Decision Theory
Estrogens
Estrogens
Fallopian Tubes
Fallopian Tubes
Female
Genital Diseases, Female
Citation neighborhood
(no data yet)
We don't have any in-corpus citations linked to this paper yet.
The paper's references may be in our DB but unresolved to
``paper_id`` (resolution happens at ingest when the cited DOI
matches a row we already have). Run the cross-source citation
reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-09-15T06:16:59.523076+00:00
- pubmed
- last seen: 2026-05-13T22:09:45.632124+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine